Lipid emulsion as a drug delivery system for breviscapine: Formulation development and optimization

Archives of Pharmacal Research

Volumn 35, Issue 6, 2012, Pages 1037-1043

  Wei, Lijun ^a   Li, Gao ^a   Yan, Yi Dong ^b   Pradhan, Roshan ^b   Kim, Jong Oh ^b   Quan, Qizhe ^c  

^a YANBIAN UNIVERSITY   (China)

^b Yeungnam University   (South Korea)

^c BEIJING UNION UNIVERSITY   (China)

Author keywords

Breviscapine; Lipid emulsion; Optimization; Scutellarin

Indexed keywords

BREVISCAPINE; GLYCEROL; LIPID EMULSION; OLEIC ACID; PHOSPHATIDYLCHOLINE; POLOXAMER; SCUTELLARIN; SOYBEAN OIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SYNTHESIS; INJECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; RAT; ROOM TEMPERATURE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG STABILITY; DRUGS, CHINESE HERBAL; EMULSIONS; FLAVONOIDS; GLYCEROL; INJECTIONS, INTRAVENOUS; LECITHINS; LIPIDS; MALE; NANOPARTICLES; OLEIC ACID; PARTICLE SIZE; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY; SOYBEAN OIL; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84864961039     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0611-z     Document Type: Article

References (31)

1. Bunjes, H., Lipid nanoparticles for the delivery of poorly water-soluble drugs. J. Pharm. Pharmacol., 62, 1637-1645 (2010).
2. Cui, W., Li, X., Zhou, S., and Weng, J., Investigation on process parameters of electrospinning system through orthogonal experimental design. J. Appl. Polym. Sci., 103, 3105-3112 (2007). (Pubitemid 46345598)
3. Das, S. and Chaudhury, A., Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech, 12, 62-76 (2011).
4. Fan, X., Liu, Q., Zhen, P., Zhang, Y., and Hu, X., Stepwise multiple regressions application in liposome orthogonal experiments. J. Chin. Pharmaceut. Sci., 16, 96-100 (2007).
5. Hao, X., Cheng, G., Sun, J., Zou, M., Yu, J., Zhang, S., and Cui, F., Validation of an HPLC method for the determination of scutellarin in rat plasma and its pharmacokinetics. J. Pharm. Biomed. Anal., 38, 360-363 (2005). (Pubitemid 40733167)
6. Hong, M. S., Lim, S. J., Lee, M. K., Kim, Y. B., and Kim, C. K., Prolonged blood circulation of methotrexate by modulation of liposomal composition. Drug Deliv., 8, 231-237 (2001).
7. Hu, X. M., Zhou, M. M., Hu, X. M., and Zeng, F. D., Neuroprotective effects of scutellarin on rat neuronal damage induced by cerebral ischemia/reperfusion. Acta Pharmacol. Sin., 26, 1454-1459 (2005).
8. Ji, C., Na, W., Fei, X., Sheng-Jun, C., and Jia-Bi, Z., Characterization, lung targeting profile and therapeutic efficiency of dipyridamole liposomes. J. Drug Target., 14, 717-724 (2006). (Pubitemid 44921530)
9. Kurihara, A., Shibayama, Y., Mizota, A., Yasuno, A., Ikeda, M., Sasagawa, K., Kobayashi, T., and Hisaoka, M., Lipid emulsion of palmitoylrhizoxin: effects of composition on lipolysis and biodistribution. Biopharm. Drug Dispos., 17, 331-342 (1996). (Pubitemid 26178151)
10. Liu, H., Yang, X.-L.,Wang, Y., Tang, X.-Q., Jiang, D.-Y., and Xu, H.-B., Protective effects of scutellarin on superoxideinduced oxidative stress in rat cortical synaptosomes. Acta Pharmacol. Sin., 24, 1113-1117 (2003).
11. Lu, J., Cheng, C., Zhao, X., Liu, Q., Yang, P., Wang, Y., and Luo, G., PEG-scutellarin prodrugs: Synthesis, water solubility and protective effect on cerebral ischemia/reperfusion injury. Eur. J. M ed. Chem., 45, 1731-1738 (2010).
12. Mulik, R., Mahadik, K., and Paradkar, A., Development of curcuminoids poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study. Eur. J. Pharm. Sci., 37, 395-404 (2009).
13. Müller, R. H., Mäder, K., and Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm., 50, 161-177 (2000). (Pubitemid 30326695)
14. Onuki, Y., Morishita, M., and Takayama, K., Formulation optimization of water-in-oil-water multiple emulsion for intestinal insulin delivery. J. Control. Release, 97, 91-99 (2004). (Pubitemid 38624512)
15. Porter, C. J. H., Trevaskis, N. L., and Charman, W. N., Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov., 6, 231-248 (2007). (Pubitemid 46344627)
16. Reddy, L. H. and Murthy, R. S. R., Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly (butylcyanoacrylate) nanoparticles. Acta Pharm., 54, 103-118 (2004). (Pubitemid 38954725)
17. Shi, S., Xu, L., Mao, Z., Li, W., Ye, J., and Gao, M., Study on physicochemical properties and influence factors on stability of breviscapine. China Journal of Chinese Materia Medica, 34, 843-847 (2009).
18. Society of Toxicology (SOT), Guiding principles in the use of animals in toxicology. www.toxicology.org/AI/FA/guidingprinciples. pdf (2008).
19. Souto, E. B. and Muller, R. H., Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb. Exb. Pharmacol., 197, 115-141 (2010).
20. Tang, J., Wei, H., Liu, H., Ji, H., Dong, D., Zhu, D., and Wu, L., Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. Drug Deliv., 7, 223-230 (2010).
21. Wang, M., Xie, C., Cai, R. L., Li, X. H., Luo, X. Z., and Qi, Y., Studies on antioxidant activities of breviscapine in the cell-free system. Am. J. Chin. Med., 36, 1199-1207 (2008).
22. Wang, M. Y., Sato, H., Adachi, I., and Horikoshi, I., Optimization of the formulation design of chitosan microspheres containing cisplatin. J. Pharm. Sci., 85, 1204-1210 (1996). (Pubitemid 26372889)
23. Wenli, L., Jianxin, G., Jin, L., Luosheng, H., and Qineng, P., Distribution of liposomal breviscapine in brain following intravenous injection in rats. Int. J. Pharm., 306, 99-106 (2005).
24. Wenli, L., Jianxin, G., Qineng, P., Yunmei, S., and Jin, L., Comparative pharmacokinetics of breviscapine liposomes in dogs, rabbits and rats. Int. J. Pharm., 359, 118-122 (2008).
25. Xiong, F., Xiong, C., Ge, L., Chen, Y.-J., Wang, H., Gu, N., and Zhu, J.-B., Preparation, characterization, and biodistribution of breviscapine proliposomes in heart. J. Drug Target., 17, 408-414 (2009).
26. Xiong, F., Wang, H., Geng, K.-K., Gu, N., and Zhu, J.-B., Optimized preparation, characterization and biodistribution in heart of breviscapine lipid emulsion. Chem. Pharm. Bull., 58, 1455-1460 (2010).
27. Xiong, F., Wang, H., Chen, Y.-J., Geng, K.-K., Gu, N., and Zhu, J.-B., Characterization, biodistribution and targeting evaluation of breviscapine lipid emulsions following intravenous injection in mice. Drug Deliv., 18, 159-165 (2011a).
28. Xiong, F., Xiong, C., Yao, J., Chen, X., and Gu, N., Preparation, characterization and evaluation of breviscapine lipid emulsions coated with monooleate-PEG-COOH. Int. J. Pharm., 421, 275-282 (2011b).
29. Yiming, L., Wei, H., Aihua, L., and Fandian, Z., Neuroprotective effects of breviscapine against apoptosis induced by transient focal cerebral ischaemia in rats. J. Pharm. Pharmacol., 60, 349-355 (2008). (Pubitemid 351269822)
30. Zhang, J., Li, X. S., and Zhang, W. D., Progress in study of chemical constituents and pharmacological activity of breviscarpus. J. Pharm. Pract., 20, 103-107 (2002).
31. Zhou, Q. S., Zhao, Y. M., Bai, X., Li, P. X., and Ruan, C. G., Effect of new-breviscapine on fibrinolysis and anticoagulation of human vascular endothelial cells. Acta Pharmacol. Sin., 13, 239-242 (1992).